Elisa de Stanchina, PhD

Facility Head

Share
Print
Share
Print
Elisa de Stanchina, PhD

Office Phone

646-888-2142

Office Fax

646-422-0246

Lab Phone

646-888-2160

Publications

Manchado E, et al. (2016) “A combination strategy for treating KRAS mutant lung cancer”. Nature 534:647-51

Rodrik-Outmezguine VS, et al (2016). “Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor”. Nature 534:272-6

Malladi S, et al. (2016).  “Metastatic Latency and Immune Evasion Mediated by Autocrine DKK1”. Cell 165:45-60

Fattahi F, et al. (2016). “Pluripotent-derived human enteric neuron lineage for combined cell and drug-based therapy in Hirschsprung’s disease”. Nature 531:105-9

LaFave LM, et al. (2015) “Loss of BAP1 function leads to EZH2-dependent transformation”. Nat Med 21:1344-9

Yao Z, et al. (2015). “BRAF mutants evade ERK dependent feedback by different mechanisms that determine their sensitivity to drugs.” Cancer Cell 28:370-83

Shih AH, et al. (2015). “Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia”. Cancer Cell 27:502-15

Maddalo D, et al. (2014). “In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system”. Nature 516: 423-7.

Schwartz S, et al. (2014). Feedback suppression of PI3Kα signaling in PTEN negative tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell  27:109-22.

Lovly CM, et al. (2014). “Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.” Nat Med. 20:1027-34

Huang CH, et al. (2014). “CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma”. Genes Dev. 15:1800-14

Wolfe A, et al. (2014). “RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer”. Nature 513: 65-70 PMID: 25079319

Clohessy JG and de Stanchina E (2013). “Infrastructure needs for translational integration of mouse and human trials”. Mouse Models of Cancer, CSHL Press: 461-66.

Piovan E, et al. (2013). “Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia”. Cancer Cell 24:766-76

Lito P, et al. (2012). “Relief of profound feedback inhibition of mitogenic signaling by Raf inhibitors attenuates their activities in BRAFV600E melanomas”. Cancer Cell 22:668-82

Zammarchi F, et al. (2011). “Anti-tumorigenic potential of STAT3 alternative splicing modulation”. Proc. Natl. Acad. Sci.USA 108-17779-84

Real PJ, et al. (2009). “Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL”. Nature Med. 15: 50-58.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Elisa de Stanchina discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures